Aims/hypothesis We assessed the relationship between BP and risk of cardiovascular events (CVEs) and all-cause mortality in patients with type 2 diabetes and renal impairment (estimated GFR<60 ml min 
Introduction
Hypertension is present in 20-55% of patients at the time of diagnosis of type 2 diabetes [1] . Elevated BP is associated with an increase in the risk of cardiovascular disease (CVD) and death in the general population [2] [3] [4] [5] ; when hypertension is combined with diabetes, the CVD risk increases further [6] . Previous studies have shown that in patients with type 2 diabetes a systolic BP (SBP) of 140 mmHg or higher increases the risk of CHD, stroke, cardiovascular events (CVEs) and allcause mortality [7] [8] [9] [10] . In addition, other studies have shown an increase in the risk of CVEs and mortality when SBP is reduced to below 120 mmHg [11, 12] . A diastolic BP (DBP) of <70 mmHg at baseline and during follow-up has been associated with a significantly increased risk of CVD [13] .
Based on these studies, a hypothesis of a J-shaped relationship between treated BP and the risk of CVEs and mortality has been proposed and is still under debate [7, 14] . The current treatment guidelines by the ADA and EASD, however, recommend a BP target in patients with diabetes of 140/ 90 mmHg unless signs of end-organ damage such as albuminuria and retinopathy are present; if so, a stricter BP target of 130/80 mmHg is recommended [15] . In patients with renal impairment (RI), the Kidney Disease: Improving Global Outcomes workgroup recommend a BP of <140/90 mmHg in the absence of albuminuria and <130/80 mmHg in the presence of albuminuria to reduce the risk of CVD. In addition, the guidelines mention that other factors such as age and cardiovascular comorbidities should be considered [16] .
Optimal BP levels in high risk patients have thus not yet been established. The aim of this study was therefore to assess the relationship between BP level and the risk of cardiovascular events and all-cause mortality in a nationwide observational study of unselected patients with type 2 diabetes and RI who were treated in clinical practice and reported to the Swedish National Diabetes Register (NDR).
Patients and methods
The NDR The NDR was initiated in 1996. Information is collected at least once yearly during patient visits and reported to the NDR. All patients provide informed consent to be registered before inclusion, and all information is stored in a central database. The Regional Ethics Review Board at the University of Gothenburg approved the study, which was performed in accordance with the Declaration of Helsinki.
We included 33,356 patients with type 2 diabetes and RI (estimated GFR [eGFR] of <60 ml min −1 1.73 m
−2
). Inclusion criteria were a diagnosis of type 2 diabetes with a reported serum creatinine value between >20 and <800 μmol/l at baseline. Reported type 2 diabetes was defined as patients having a reported treatment with diet only or with oral glucoselowering agents only, or an onset of diabetes at 40 Examinations at baseline BP was determined as the mean value of the reported BPs from baseline to an endpoint or the end of the study (usually with annual reporting). All BPs used in this study are the BPs reported to the NDR, and according to the instructions they should be taken according to Swedish standard for BP recording. The Swedish standard for BP recording is the mean value (mmHg) of two supine readings (Korotkoff I-V) with a cuff of an appropriate size, after at least 5 min of rest. Analyses of serum creatinine, HbA 1c and blood lipids were performed at local laboratories. Renal function expressed as the eGFR (in millilitres per minute per 1.73 m 2 ) was calculated using the Modification of Diet in Renal Disease study equation [17] . Albuminuria was defined as micro-or macroalbuminuria, i.e. a urinary AER of 20-200 or >200 μg/min in two out of three consecutive tests at baseline. A smoker was defined as a patient who smoked one or more cigarette per day or used a pipe, or who had stopped smoking within the past 3 months.
Follow-up and definition of endpoints Patients were followed from the baseline examination (between 1 July 2005 and 31 December 2007) until a first CVE (primary endpoint) and/or death, or otherwise until 31 December 2011. The mean follow-up time was 5.3 years. A CVE was defined as CHD, stroke or peripheral arterial disease (PAD), whichever came first, and the definition of CHD was myocardial infarction (MI) (ICD-10 code I21; www.who.int/classifications/icd/en/), unstable angina (ICD-10 code I20.0), percutaneous coronary intervention and/or coronary artery bypass grafting. Fatal CHD was defined as ICD-10 codes I20-I25, stroke was defined as non-fatal or fatal cerebral infarction, intracerebral haemorrhage or unspecified stroke (ICD-10 codes I61, I63, I64 and I67.9), PAD (ICD-10 codes I70.2, I73. 1, I73.9 and I79.2) and congestive heart failure (ICD-10 code I50) [18, 19] . Data on all events were retrieved by data linkage with the Swedish Cause of Death and the Hospital Discharge Registers (National Board of Health and Welfare, Sweden), which is a reliable validated alternative to revised hospital discharge records and death certificates [20, 21] .
Statistical methods Baseline clinical and biochemical characteristics are presented as mean values±SD or as proportions (n, %) in Table 1 . Patients were categorised into ten groups (deciles) according to SBP or DBP (approximately 3,336 patients in each group). We used time-dependent Cox models to estimate HRs with 95% CIs to examine the relationship between the two mean BPs, the SBP and DBP levels, CVEs and all-cause mortality. Proportional hazards assumptions were established for all time-dependent covariates. Models were adjusted for the following covariants: age, sex, diabetes duration HbA 1c , BMI, LDL-cholesterol, the ratio between serum triacylglycerol and HDL-cholesterol, smoking, a previous history of CVD and chronic heart failure (CHF), ongoing treatment with antihypertensive, lipid-and glucose-lowering medications. Crude associations between BP and cardiovascular outcome with and without adjustment for potential confounders were examined in different models. The group with lowest cardiovascular outcome rate was used as the reference group (HR=1). Interactions between mean SBP or DBP and the covariates were tested by maximum likelihood estimation and found to be non-significant (p>0.05) for all covariates.
In order to analyse non-linear relationships, we included both SBP and the squares of SBP for CVE (1-survival rate) in the Cox model; the same analyses were performed for DBP. We also created splines with nine knots at the decile using the Transreg procedure (Figs 1, 2 ). All statistical analyses were performed in SAS V. 9.3 (SAS Institute, Cary, NC, USA) [22] . Table 2 and the 6 year CVD (= CVE) rate ; thus, the majority of patients with RI had stage 3 chronic kidney disease. Seventy per cent of patients with RI were normoalbuminuric and one-third of patients with RI had previous CVD at the beginning of the study (shown in ESM Table 1 ). Clinical and biochemical characteristics of patients with type 2 diabetes and RI with and without albuminuria at baseline are shown in Table 1 . Sixty per cent of patients with albuminuria had microalbuminuria and 40% had macroalbuminuria. Patients with albuminuria had a significantly longer diabetes duration, worse glycaemic control, higher mean SBP but lower DBP, i.e. a higher pulse pressure (PP), in spite of more antihypertensive treatment compared with normoalbuminuric patients. Patients with albuminuria were more often men and smokers and more often had a history of CVD, CHF and retinopathy at baseline.
Association between SBP and both cardiovascular events and all-cause mortality in patients with RI During the follow-up period, 11,317 (34%) CVEs were observed, including 7,704 (23%) episodes of CHD and 2,284 (6.8%) of stroke. Overall, 10,738 (32%) patients died. The two most common causes of death were CVD (34%) and malignancies (18%). Table 2 Table 3 , and the 6 year CVD (= CVE) rate Table 2 . When using only the initial reported SBP at baseline instead of the overall reported mean SBP, overall HRs were lower and a significantly higher HR was found only for allcause mortality in the lowest SBP interval (80-120 mmHg, HR 1.25 [95% CI 1.10, 1.41]; ESM Table 3) .
As SBP and/or DBP may change prior to a CVE or death, we performed analyses in which we censored the last reported SBP before a CVE or death (ESM Table 4 ). In these analyses, we found the highest risks in the lowest and highest SBP intervals of both CVEs and all-cause mortality (in a similar pattern). However, the HRs were lower overall than when mean BPs were used for CVEs (HR Unadjusted analyses assessing the relationship of both SBP and DBP with CVE or all-cause mortality show similar patterns, but the magnitudes of risk (i.e. HRs) are higher for all BP groups (data shown in ESM Tables 5 and 6 ).
When patients with prior CVD and/or CHF were excluded, findings were very similar to those previously described, such that the lowest and highest SBP levels were still associated with the highest risk of CVEs and all-cause mortality (shown in ESM Table 7 ). It should, however, be noted that the HRs for CVEs and all-cause mortality were somewhat higher overall in the different SBP intervals when comparing patients without prior CVD and/or CHF with all patients.
In addition, stratification for the absence or presence of albuminuria did not alter results substantially (shown in ESM Table 8 and 9 ). However, it should be noted that the HR for CVE in the lowest SBP group was slightly higher for normoalbuminuric patients than for those with albuminuria (HR 2.4 [95% CI 2.1, 2.8] vs HR 2.2 [95% CI 1.8, 2.6], respectively).
Unadjusted analyses of interaction between both SBP and DBP and potential confounders on risk of CVE and all-cause mortality were also performed. These data for are shown in ESM Tables 10 and 11 .
The non-linear spline of the 6 year rate of CVEs by mean SBP as a continuous variable is shown in Fig. 1 . The risk of CVE was adjusted as described for the Cox model in Table 2 . A progressively increased risk of CVEs was seen with both SBP <110 mmHg and SBP >150 mmHg. In addition, and interestingly, slight increases in risk of CVEs were found for SBPs of 130 and 140 mmHg. These increases in HRs mirrored the results found in the Cox model for the SBP intervals 128-131 and 139-142 mmHg in Table 2 .
Association between DBP and both cardiovascular events and all-cause mortality in patients with RI Table 12 .
In a complementary analysis, we censored the last reported DBP before a CVE or death (data presented in ESM Table 13 ). The highest risks of CVEs and allcause mortality were found in the lowest and highest DBP intervals but the HRs were lower overall compared with using the mean BPs, except for all-cause mortality in the highest DBP interval (83-125 mmHg), where the HRs were nearly identical in the two different analyses (HR 2.3 [95% CI 2.0, 2.6] for both).
The non-linear spline of the 6 year rate of CVEs with mean DBP as a continuous variable is shown in Fig. 2 . The risk of CVE was adjusted as described for the Cox model in Table 3 Tables 15 and 16 .
Discussion
In this nationwide observational study of more than 30,000 patients with type 2 diabetes and RI followed for a median of 5.3 years, we confirm that patients with the lowest and highest mean systolic and diastolic arterial BP intervals are exposed to the highest risks of CVEs and all-cause mortality. A SBP level of 135-139 and a DBP level of 72-74 mmHg were associated with the lowest risks of CVEs or death in this cohort of patients. A low PP was associated with a high risk of death, but a high PP was associated with an increased risk of a CVE.
Clinical trials have previously shown that a high BP increases the risk of CVEs (especially stroke) and all-cause mortality in patients with type 2 diabetes [23, 24] . However, in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) BP study in patients with nearly to normal renal function, a target SBP of ≤120 mmHg did not reduce the risk of major CVE compared with a SBP of ≤140 mmHg [10] . Also, in a subgroup analysis of participants with diabetes and coronary artery disease in the International Verapamil SR-Trandolapril (INVEST) study, tight control of SBP (≤130 mmHg) was not associated with improved cardiovascular outcomes compared with conventional BP control (130-140 mmHg), and a non-significant increase in the rate of allcause mortality was noted with tight BP control [11] . A J-shaped relationship was found in the Veterans Affairs Diabetes Trial (VADT), in which a higher risk of CVEs was found in patients with SBP ≥140 mmHg and DBP <70 mmHg [13] .
Fewer studies have addressed the association between low BP levels and mortality in patients with diabetes and mild to moderate RI, and these studies have reported slightly varying results. In a post hoc analysis of the Irbesartan Diabetic Nephropathy Trial (IDNT), 1,590 patients with type 2 diabetes, albuminuria and mainly mild renal dysfunction, SBP of <120 mmHg was associated with a higher risk of CV mortality and CVEs. In addition, DBP of <85 mmHg was associated with a non-significantly higher risk of all-cause mortality and a significantly higher risk of MI but lower risk of stroke [25] . In the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) trial in which 24% of all participants had type 2 diabetes, there was no improvement in fatal or non-fatal CVEs, except for stroke, when reducing the SBP below 130 mmHg [26] . Similar results were later found in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) and the Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) trials: findings showed no benefit with respect to mortality or CVEs and that intensive treatment with dual reninangiotensin-aldosterone system (RAAS) blockade even may even be harmful. The effects of BP lowering and/or RAAS blockade are therefore still under debate [27, 28] .
A J-shaped relationship between BP and CVEs or mortality has been discussed in several reports and was, for example, found in the VADT where a higher risk of CVEs was seen in patients with SBP ≥140 mmHg and DBP <70 mmHg [13] , Table 3 Incidence of stroke, CHD, stroke, CVEs, all-cause mortality and HRs of CVE and all-cause mortality by deciles of mean DBP a DBP interval (mmHg)
All-cause mortality (n/%) indicating that both too high BP and too low BP are associated with an increased risk of CVEs and mortality [13] . In patients with RI, a low BP is likely to be a marker of either pre-existing CVD (including CHF) or treatment of these conditions with agents with BP-lowering properties, or both [29, 30] . In the present study, a more U-shaped relationship was observed between mean BP levels and CVEs despite the fact that only 15% of participants had a history of CHF at baseline and that patients with an eGFR of <15 ml min −1 1.73 m −2 were excluded. The mean eGFR was 48±9 ml min −1 1.73 m −2 ; thus, most patients had only mild to moderate RI. Even so, the number of cardiovascular events and deaths during the follow-up period was very high (CVEs 34%, all-cause mortality 32%) compared with previous studies [31, 32] . When we omitted/censored the last reported BP before a CVE or death, a similar U-shaped pattern was found but the risk estimates were somewhat lower than when using the mean of all BP measurements reported during follow-up. One potential explanation for this U-shaped relationship may be that in this study we divided patients into BP deciles and not according to static BP values, as has been done in other studies.
The risk of CVEs and all-cause mortality was also significantly higher for the lowest and highest MAP intervals (53-85 and 107-153 mmHg). MAP is highly correlated with SBP and DBP, and its value as a better predictor of CVD than SBP and/ or DBP has therefore been questioned [33, 34] .
We also evaluated the association of PP with both CVEs and all-cause mortality. A high PP is mainly related to increased stiffness in the large arteries, as opposed to a low PP, which is often a marker of low SBP or, rarely, of isolated diastolic hypertension. PP is recognised as a predictor of CVEs and, in agreement with other studies, our result also showed that the risk of CVEs or all-cause mortality is greater for the highest PP interval (85-154 mmHg) [35, 36] . The high risk of death for the lowest PP interval (15-49 mmHg) is likely to be a consequence of low SBP. In this study, the relationship between PP and CVEs was relatively weak and became even weaker when PP was adjusted for MAP. This is consistent with the results of previous studies on the relationships between different BP indices and cardiovascular outcomes [37] [38] [39] .
Albuminuria was found only in 30% of patients with RI at baseline, in line with previous studies in which the majority of patients with type 2 diabetes and RI were found to be normoalbuminuric [40] [41] [42] . Both albuminuria and RI are independent risk factors for CVEs and all-cause mortality in type 2 diabetes, with albuminuria being the strongest risk factor and relevant at all levels of renal function. However, in normoalbuminuric patients, a slight reduction in renal function is an important predictor of CVEs and all-cause mortality [43] . The observation that the majority of patients were normoalbuminuric is of interest because treatment guidelines generally recommend even lower BP targets in patients with albuminuria [16] . Although albuminuria has been recognised as a risk factor for CVEs and mortality, adjustments for the presence of albuminuria did not markedly alter the results in the present study [44] . However, an interesting finding of this study was that the risk of CVEs in the lowest BP interval was actually slightly higher for normoalbuminuric patients than for those with albuminuria.
The major strengths of this cohort study are the nationwide scale, large number of patients and the many person-years of observation and number of events. We included patients who received routine treatment according to national guidelines in both primary and secondary care, supporting high external validity and generalisability of our findings to other type 2 diabetes populations. In this study, participants were divided into deciles to reflect the true variation in BP readings, instead of using the traditional BP cutoffs. However, there are some limitations to this study. Since this is an observational study, a cause-effect relationship cannot be established. Moreover, the data were reported by different medical centres and laboratories, which may have slightly affected the accuracy of the data. Only clinical BP measurements were used in this study and not ambulatory BPs, which could be an even better predictor of cardiovascular risk [45, 46] . However, less than 20% of participants had only one reported BP measurement during the study period. It is also plausible that the true BP value for some patients in these BP intervals were higher when measured at the centres, but rounded downwards when reporting in order to comply with national treatment guidelines. This, we think, might explain the slight variation in risk seen for the lower BP intervals, i.e. participants with an SBP interval of 139-142 mmHg or a DBP interval of 78-80 mmHg were shown to exhibit an increased risk of CVE and all-cause mortality compared with those with either a lower or a higher achieved BP. Thus, if a high risk of CVD is attributed to false low BP readings and a CVE occurs, then this is likely to occur. Further standardisation of BP measurements using automated methods could possibly reduce such bias.
In conclusion, the risk of cardiovascular disease and allcause mortality was very high in patients with type 2 diabetes and RI in clinical practice, and increased significantly with both high and low SBP and DBP in a U-shaped manner. A SBP of 135-139 mmHg and a DBP of 72-74 mmHg were associated with the lowest risks of CVE and all-cause mortality.
Some of the data in this paper has previously been presented as an abstract at the 51st ERA-EDTA congress, Amsterdam, the Netherlands, 31 May-3 June 2014.
Funding Supported by grants from the Swedish government (under the Avtal om Läkarutbildning och medicinsk Forskning [agreement for medical education and research]). This work was also supported by grants for research and medical education from Skaraborgs Hospital, Skövde, Sweden (project number 53340).
Duality of interest MKS is currently employed by Amgen AB. The other authors declare that there is no duality of interest associated with their contribution to this manuscript.
Contribution statement All authors researched the data; MP, A-MS and HA performed the statistical analyses; HA and MKS drafted the manuscript; and all authors reviewed and contributed to the manuscript and thereafter approved the version to be published. MKS is the guarantor of this work.
